![Photo: Alexander Zamora, Partner at Capiton, his focus is healthcare (© Capiton)](https://cdn.fyb.de/wp-content/uploads/2024/07/alexanderzamora-capiton-capiton-400x394.jpg)
KD Pharma Group acquires Marine Lipids from dsm-firmenich
Berlin — KD Pharma Group (“KD Pharma”), a leading CDMO in the field of pharmaceutical and nutritional lipids and portfolio company of Capiton, announces the acquisition of the Marine Lipids business of dsm-firmenich.
As part of the transaction, dsm-firmenich will acquire a minority stake in KD Pharma and become a co-shareholder alongside the Capiton Omega Continuation Fund vehicles and other minority shareholders.
The transaction will close during 2024, subject to customary regulatory approvals, and includes dsm-firmenich’s Marine Lipids fish oil omega‑3 business for the dietary supplement and pharmaceutical markets, together with the manufacturing facilities in Piura, Peru, and Mulgrave, Canada.
This transaction will create a well-equipped player in the marine lipids market by combining the best of the two companies and their respective expertise with the scale of dsm-firmenich’s sites in Piura and Mulgrave and the high concentration capability of KD Pharma.
The enlarged KD Pharma Group will benefit from the expanded product range and customization capabilities supported by the increased production capacity.
Oscar Groet, CEO of KD Pharma, said: “We are delighted to welcome dsm-firmenich’s Marine Lipids portfolio to KD Pharma, a move that fits perfectly with our strategic vision to become the technology leader in lipids.”
Further information can be found at KD Pharma Group News.
https://kdpharmagroup.com/ capiton AG and KD Pharma Group were advised by Jefferies as buyer advisor, CMS Hasche Sigle, Baker McKenzie, A&O Shearman, EY, BDO, Herter & Co.
— A Teneo Company, Roland Berger and Howden M& A.
The transaction was notarized by Dr. Patrick Auerbach (NEON) and is subject to customary regulatory approvals.